Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 218Recurrence 24Neoplasms, Plasma Cell 15Immunoglobulin Light-chain Amyloidosis 13Neoplasms 12Lymphoma, Non-Hodgkin 6Smoldering Multiple Myeloma 5Leukemia, Myeloid, Acute 4Plasmacytoma 3Paraproteinemias 3Leukemia, Plasma Cell 3Hematologic Neoplasms 3Hematologic Diseases 3Amyloidosis 3Neoplasm, Residual 2Hodgkin Disease 2Disease 2Corneal Diseases 2Blood Protein Disorders 2Acute Kidney Injury 2Triple Negative Breast Neoplasms 1Renal Insufficiency 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Personal Satisfaction 1Patient Satisfaction 1Patient Preference 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1

Interventions

Dexamethasone 6Lenalidomide 4Cyclophosphamide 4Melphalan 3daratumumab 2carfilzomib 2Prednisone 2ricolinostat 1pomalidomide 1deltacortene 1Transplantation, Autologous 1Thalidomide 1Calcium Dobesilate 1Bortezomib 1Bone Marrow Examination 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Disease × daratumumab × Plasma cell × Clear all
NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

European Myeloma Network B.V.

Phase 2 Active not recruiting
401 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Anaveon AG

Phase 1 Terminated
4 enrolled
Plasma cell

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡